On Tuesday, 1659 stocks advanced, 2521 declined and 172 remained unchanged on Bombay Stock Exchange with advance decline ratio of 0.66 indicating a negative closing. The trend of the major indices on Tuesday’s trading is given in the table below.
On NSE, 106 securities advanced and closed at a new 52-week high whereas 100 securities sank to close at their new 52-week lows. Nifty Pharma, Nifty PSU Bank and Nifty IT among the biggest gainers. Nifty Infrastructure, Nifty Media and Nifty Energy among the biggest losers.
India’s competition regulator Competition Commission of India (CCI) has found Tata Steel (+0.26%), JSW Steel (-0.81%), SAIL (-2.92 %) and 25 firms guilty of colluding on steel prices. 56 executives, including top leaders, were held personally liable for roles between 2015–2023. The probe, launched in 2021 after builder complaints, is among India’s most high‑profile antitrust cases. Searches at smaller firms widened the inquiry to 31 companies and industry bodies.
KPIT Technologies (-0.96%) unveiled its Agentic AI solution suite at CES 2026, built on Microsoft’s AI infrastructure. The modular, cloud‑ready ecosystem aims to tackle software complexity, defect rates, and faster delivery needs in mobility. Pilot programs in connected vehicle and autonomy production are already helping OEMs redesign workflows across planning, development, and quality engineering, marking a step change in automotive software lifecycle management.
ICICI Bank received PFRDA approval (Jan 5, 2026) to acquire 100% stake in ICICI Prudential Pension Funds Management Company Ltd from ICICI Prudential Life Insurance. The clearance allows ICICI Bank to become the sponsor of ICICI PFM, making it a wholly owned subsidiary. The acquisition, subject to compliance conditions, marks a strategic expansion into pension fund management, strengthening ICICI Bank’s role in the retirement planning ecosystem.
Torrent Pharmaceuticals (+1.73%) board cleared fundraising of up to ₹12,500 crore via secured, rated, listed NCDs (non‑convertible debentures) on a private placement basis, to be issued in one or more tranches. The move, approved by the Securities Transfer & Stakeholders Relationship Committee, follows its ₹19,500 crore acquisition plan for J B Chemicals (June 2025), underscoring capital mobilisation for strategic expansion.
GM Breweries posted a robust Q3 FY26 performance, with net profit up 91% y-o-y to ₹42 crore on festive demand and operating leverage. Revenue rose 22% y-o-y to ₹202.5 crore, supported by volume traction and better realisations. EBITDA jumped 80% YoY to ₹53 crore, with margins expanding over 800 bps to 26.1%, reflecting cost control, efficiency gains, and a favourable mix.
The top gainers and top losers of the major indices are given in the table below:
The closing values of the major Asian indices are given in the table below:
Market This Week
Moneylife Digital Team
02 January 2026
While the NIFTY and the Sensex posted modest gains of 10% and 9%, respectively, in 2025—trailing the huge surges seen in Korea and Brazil, the appetite for new issuances remains voracious as the Indian primary market is preparing for...
Weekly Moneylife Indices & Sector Trends
Moneylife Digital Team
02 January 2026
INDIAN MARKET TRENDS
From 26 December 2025 to 1 January 2026, ML Micro-cap Index rose 3%. ML Mega-cap Index and ML Small-cap Index rose 1% each. The NIFTY, ML Mid-cap Index, ML Large-cap Index and the Sensex ended flat.
...
Wealth Creators Series 2015-25- Part-1: A Snapshot of Wealth-Creation over the Past 10 Years
Sher Singh Yadav
and
Pratibha Kamath
02 January 2026
Entering its 20th edition, our ‘Wealth Creators’ series’ is, once again, offering insights that aim to engage as well as inform. In line with our long-standing approach, we will examine stocks and sectors that have generated the...
Indegene: Turning Regulatory Complexity into Recurring Revenue
Moneylife Digital Team
01 January 2026
The global life sciences sector, encompassing bio-pharmaceuticals and medical devices, reached an estimated US$200bn (billion) in 2024, registering 5.3% growth from 2023. This expansion has been driven by targeted therapy adoption,...
